News blog

MS treatment shows success in clinical trials

It is what multiple sclerosis sufferers have long hoped for, a drug that can not only halt the progression of nerve damage caused by the disease but also reverse it (see ‘Antibody offers hope for multiple sclerosis treatment‘). Yet as the monoclonal antibody alemtuzumab clears its last hurdle before clinical approval it now seems clear it will come at a price. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE